da-9701
Dyspepsia
Seoul National University HospitalPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Dyspepsia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TANNIC ACID Hospital Infantil Cândido Fontoura | Phase 3 | BB |
LIDOCAINE Hospital Infantil Cândido Fontoura | Phase 3 | BB |
N-(P-(2-(DIMETHYLAMINO)ETHOXY)BENZYL)VERATRAMIDE Abbott | Phase 3 | BB |
Fasinumab Regeneron Pharmaceuticals | Phase 2 | CC |
Same molecule, other indications
da-9701 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →